Breaking News
Get 40% Off 0
💰 Buffett reveals a $6.7B stake in Chubb. Copy the full portfolio for FREE with InvestingPro’s Stock Ideas tool Copy Portfolios
Close

Aptevo Therapeutics Inc (APVO)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Aptevo Therapeutics's earnings

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
0.8255 +0.0175    +2.17%
- Real-time Cboe. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
  • Volume: 67,130
  • Bid/Ask: 0.0000 / 0.0000
  • Day's Range: 0.7910 - 0.8492
Aptevo Therapeutics 0.8255 +0.0175 +2.17%

Aptevo Therapeutics Inc Company Profile

 
Get an in-depth profile of Aptevo Therapeutics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

40

Equity Type

ORD

Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. It develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. The company’s lead clinical blood cancer candidate is APVO436 that is in Phase 1b/2 clinical trial for acute myelogenous leukemia. It is also developing ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for NSCLC, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate for multiple solid tumors; APVO442, a novel bispecific candidate based on the ADAPTIR-FLEX platform technology for multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate for prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

Contact Information

Address 2401 4th Avenue Suite 1050
Seattle, 98121
United States
Phone 206 838 0500
Fax 206 838 0503

Top Executives

Name Age Since Title
Marvin L. White 59 2016 President, CEO & Director
Barbara Lopez Kunz 64 2016 Independent Director
Daniel J. Abdun-Nabi 67 2016 Independent Director
Zsolt P. Harsanyi 78 2016 Independent Director
John E. Niederhuber 83 2016 Independent Chairman
Grady Grant 66 2016 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

APVO Comments

Write your thoughts about Aptevo Therapeutics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
matanel liberman
matanel liberman Nov 24, 2021 12:04PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Back to 15
Financial Advisors
Financial Advisors Nov 24, 2021 6:12AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
any prediction for today ?
Bharath Kumar
Bharath Kumar Nov 23, 2021 1:56PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Crazy volume lets go!!! 30 for sure before close
anonimous anonimous
anonimous anonimous Nov 23, 2020 6:01AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what are your thoughts about today guys?
anonimous anonimous
anonimous anonimous Nov 23, 2020 5:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
we are faaacked
Paul Manning
Paul Manning Nov 10, 2020 6:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what will tomorrow bring...
Farry Hardianto
Farry Hardianto Nov 08, 2020 6:15AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
More than doubled AH!
Ab High
Ab High Nov 04, 2020 3:28PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to 20$
blah blah
blah blah Mar 29, 2020 8:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Company might crash in the next week. Take a look at how many institutional investors are shorting them.
Raoul Alexander
Raoul Alexander Mar 29, 2020 8:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
How do you find that info?
Farry Hardianto
Farry Hardianto Mar 29, 2020 8:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
That institutional investor might have crashed.
Catalina III de Foix
Catalina III de Foix Mar 29, 2020 8:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What do you think about IBIO? Thanx.
Manuel Martin
Manuel Martin Mar 29, 2020 8:43AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
LOL buyout at $50
jay do
jay do Mar 27, 2020 3:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
now is a good time to buy anyone?
Cody Hall
Cody Hall Mar 27, 2020 3:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cant Hurt. Expect a dip Monday and a big up later next week.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email